Issue# 1490 |
|
| Ingen Receives $100,000 Purchase Order From Oxygen Supplier for New Oxyview-Nasal Cannula |
YUCAIPA, Calif., July 17, 2009 -- Ingen Technologies, Inc.a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 Oxyview-Nasal Cannulas.
"This is a positive indication that the new Oxyview Nasal Cannula is attractive to oxygen suppliers on a global basis," stated Thomas J. Neavitt, Chief Financial officer for Ingen Technologies.
The Oxyview flow meter is a significant advance in the technology. When first launched in November 2007, it represented a new generation of pneumatic real-time safety devices. It has some notable features: accurate to within plus-minus 3% and versatile enough to work with all respiratory equipment -- CPAP, concentrators, liquid and gas cylinders, on-demand conservers and more. It is not gravity-dependent and so can be placed at any point in the tubing, even by the patients themselves. Having the device close by for easy viewing allows the patient assurance and confidence, knowing that there is a flow of oxygen at the correct level. They are also able to quickly see if the regulator or concentrator is not working properly.
Further benefits are that Ingen Technologies manufactures the reusable Oxyview device that retails for $24.95 and comes with a life-time warranty. The company also manufactures the new disposable Oxyview Nasal Cannula for adults, children and infants. This novel device sells for only $5.75 and is a quality soft-tip cannula. The infant device measures either from 0-6 liters/minute or from 0-3 liters/minute in increments of one-quarter.
The significance of this new device is that it encompasses the flow device within a cannula -- the flow meter cannot be removed and the entire assembly is ultimately disposable. Yet the cost is comparable to the cost of a conventional cannula, but with all the benefits of Oxyview. Although budget constraints are hitting everybody hard, the Oxyview Nasal Cannula should greatly decrease unnecessary service calls. So the investment made in the cost of the devices can be recovered by not incurring the expense of those unnecessary calls. It is a straightforward financial justification!
Regulatory requirements are also a factor. Gary Scalf, V/P Respiratory Operations for Specialized Medical Services, Milwaukee, WI has commented that some state inspectors are starting to require a quick and simple visual detection of oxygen flow. In his opinion, the Oxyview meets these requirements.
And most important of all is the response from patients. They are very pleased with the Oxyview and not surprisingly, report that it meets their need to be reassured that oxygen is being supplied when and where it matters most. That is the ultimate benefit.
We all need oxygen in the right place at the right time and at the right concentration. For those requiring supplemental oxygen, these criteria are even more critical. The Oxyview not only allows the patient to be reassured about delivery and flow of oxygen, but also does so with considerable economic benefits to the supplier. Everyone benefits from this simple, elegant and effective device!
About Oxyview:
Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where, in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyviews cost less than a single service call.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
| INGEN TECHNOLOGIES, INC. Stock Symbol :: IGNT |
|
 | INGEN TECHNOLOGIES, INC. (IGNT) Ingen, Inc. manufactures medical devices and provides related services for medical and consumer markets primarily in the United States. | |||||||||||
Ingen Technologies, Inc. 35193 Avenue "A" Suite-C Yucaipa, CA 92399 Phone: (800) 259-9622 Fax: 800-777-1186 |
Similar Companies in Sector · American Homepatient, Inc. provides home healthcare services and products consisting primarily of respiratory therapy services, home infusion therapy services, and the rental and sale of home medical equipment and home health care supplies. The Company’s services and products are paid for primarily by Medicare, Medicaid, and other third-party payors. OTCBB:AHOM Recent Price: $.210 |
| Current Projects |
 | Oxyview Reaches Out to Entire COPD Community in the $4 Billion Respiratory Market Ingen Technologies, Inc. recently announced that Oxyview was published in the March-2009 issue of HomeCare Magazine, and in the Spring-2009 issue of COPD Digest . COPD, chronic obstructive pulmonary disease, was the underlying cause of 718,077 U.S. deaths in 2000-2005, and it was the underlying cause of about 1 in 20 U.S. deaths for 2005 alone. With more than 20 million Americans diagnosed with COPD and another 12 million projected as being undiagnosed, Oxyview has an annual estimated projected revenue of $30M in the USA, and much greater in the global arena with an expected 600M COPD victims worldwide. | Ingen is Granted Patent Rights for China in Estimated $200M Market
Ingen Technologies, Inc. has announced that the Chinese State Intellectual Property for the People's Republic of China is prepared to grant patent rights for Oxyview. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought, according to researchers in Guangdong. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought. According to an estimation by the World Health Organization, COPD ranks first among the burdens of diseases in China and accounts for one million deaths and five million disabilities each year.
|
| Company Overview |
Ingen, Inc . (OTC.PK: IGNT) Ingen Technologies brings over 20 years of experience and dedication to the design and support of medical devices, Ingen has helped many medical professionals meet clinical and economic objectives. Ingen has developed medical products that provide a valuable benefit to the patient and cost savings to the insurance companies, Medicare and essentially the tax payer. The medical products provide a focus for the ever-increasing elderly population. These products are superior to any of our competition and they allow for effective medical product availability to seniors. Ingen’s Mission: Our Commitment to CustomersIngen is committed to meeting the needs of our customers through ongoing product innovation and support. Ingen distributes its products through a national distributor network domestically and in Canada, Asia and European Communities. Ingen’s commitment to customers continues beyond the sale of our product. The BeginningIngen, originally a privately owned company founded for the purpose of providing medical solutions for our growing healthcare market, is now a publicly traded company and growing medical device manufacturer. In 1999, Ingen founders invested several millions of dollars in the research and development of state-of-the-art respiratory monitoring devices, with a focus on helping patients and preventing unnecessary costs to the healthcare system. With multiple patents, FDA classification and certifications, Ingen is the largest manufacturer of gravity-independent in-line oxygen flow meters, meeting the demand of the growing patient population and service providers. Our products are manufactured in the USA. Our CapabilitiesWe are proud of our capabilities in gas flow-meter technology and wireless digital data transfer of gas flow rate processing. Ingen is the first company to patent and develop transducers that detect oxygen flow rate and provide data transfer. This has revolutionized the oxygen therapy market providing user friendly solutions in monitoring oxygen levels and oxygen delivery systems. Ingen Technologies, Inc. introduces Oxyview® , the World's First Patient In-Line Oxygen Flow-Meter. Another innovative respiratory product manufactured in the USA by Ingen Technologies; providing more confidence and assurance to patients using oxygen. Oxyview® is reusable, requires no batteries, works all the time in any position with all liquid or gas O2 systems, and easily installs anywhere below the cannula nearest the patient where oxygen flow matters the most. Oxygen suppliers and patients will appreciate that Oxyview® prevents many unnecessary service calls. Ingen Technologies is now offering a quality organic health supplement for patients using home oxygen therapy, and also to anyone else who is interested in healthy life styles. As a part of wellness, we are now offering the new Poga Moonga products. Poga Moonga includes a substance referred to as Moringa, and is extracted from the Moringa Tree. Ingen provides a drink or capsule that is efficiently absorbed by the bodies metabolism. One bottle is 25.35 Ounces. The instructions say to take 1-3 oz daily, therefore one bottle should last between 8-25 days. A purchase includes 4 bottles or 1-3 months supply depending upon use. Author Sanford Holst in “Moringa, Nature’s Medicine Cabinet,” writes,"... it is said the Moringa tree prevent 300 diseases. Ancient Roman, Greek and Egyptian civilizations used...the (Moringa Tree)...It is best known as an excellent source of nutrition and a natural energy booster. Loaded with nutrients, vitamins and amino acids, it replenishes your body and provides what you need to through a hectic weekday or active weekend..." It produces long-lasting energy without hyperactivity...a nerve system at rest...a blood system not under pressure...a gland and hormone system in balance." An L.A. Times article said,Scientifically speaking, Moringa sounds like magic. It can rebuild weak bones, enrich anemic blood and enable a malnourished mother to nurse her staving baby. Doctors use it to treat diabetes in West Africa and high blood pressure in India...And, it’s not only good for you, it’s delicious." Mark Fritz, L.A. Times. Perhaps the most remarkable thing about the Moringa is that it has such incredible health benefits over a wide-range of health issues. Here are but a few:
In short some studies have proved Moringa leaves effective for treating,
Seeds are used for,
Leadership
|
| Market Snapshot |
|
| News |
- Ingen Receives $100,000 Purchase Order From Oxygen Supplier for New Oxyview-Nasal Cannula
July 18, 2009 - Ingen Annual Shareholder Meeting Rescheduled for September 22,2009
July 15, 2009 - Ingen Hires Firm to Complete GSA Contract for Government Buying
July 14, 2009 - Ingen Gears-Up to Introduce New Low-Flow Oxyview Infant Nasal Cannula to Infant and Neonatal Respiratory Markets
July 10, 2009 - Letter to Shareholders From Chairman of Ingen Technologies, Inc.
July 8, 2009 - Ingen Ahead of Schedule With Product Distribution and Debt Reduction
July 1, 2009 - Ingen to Seek 5 to 7 Cents a Share On Future Buyout
June 30, 2009 - Ingen to Hire Investment Banker for Sale of Company
June 29, 2009 - Ingen's New Oxyview-Nasal Cannula to be Debuted On Front Cover of Medco Forum's National Chest Physicians Issue
June 29, 2009 - Ingen Begins Ad Campaign and Branding of the New Oxyview Nasal Cannula
June 25, 2009 - Ingen Files Annual Financial and Disclosure Ending May 31, 2009
June 25, 2009 - Ingen's New Oxyview-Nasal Cannula Initiates Market Introduction Tomorrow
June 23, 2009 - Ingen Increases Oxyview Inventory to 162,000 Units for Projected Sales Demands
June 18, 2009 - Ingen Opens Acquisition Possibilities During Growth Period
June 18, 2009 - Ingen Receives First Lot of the New Oxyview-Cannula to Prepare for Initial Orders
June 12, 2009 - Congratulations to all on IGNT
June 9, 2009 - Ingen Receives Good Response From National Advertisment in COPD Digest
June 8,2009 - Congratulations to all on IGNT
June 8, 2009 - Ingen Pays Down Debt to Increase Shareholder Value
June 5, 2009 - New featured Report on OTCReporter.com IGNT
No comments:
Post a Comment